Rich rborncamp@xmission.com
Brio Device, LLC is a medical device company and spin-out of the University of Michigan Medical Innovation Center based in Ann Arbor, MI. Brio develops airway management devices and intubation instruments.
PROBLEM: High Intubation Failure
There are 20M+ intubations performed in the US every year. Depending on setting and skill of the clinician, failure rates range from 2% - 40% resulting in approximately 2,000,000 intubation failures every year. Intubation, the procedure to insert a plastic tube into the trachea, requires significant expertise and experience to do well. With current products in the market, the tube often is inserted multiple times before it is properly placed, resulting in damage to the patient such as broken teeth, torn vocal cords, or insertion into the stomach leading to aspiration and pneumonia. Three main factors affect intubation success rates: the user’s experience level, having directional control of the tube during insertion, and continuous visualization appreciated in bronchoscopes. Clinicians need a single go-to device which is appropriate for use both in routine intubation and difficult airway cases offering guidance, maneuverability and visualization necessary to be successful. Failed intubation is the most common preventable cause of trauma-related deaths. Approximately 180,000 deaths per year list complications associated with failed intubation.
SOLUTION: Brio’s Articulating & Video Stylets
Brio is introducing a suite of products intended to improve intubation success rates for planned and emergent intubations, minimizing reliance on clinician skill for success. The products range from disposable mechanical devices to devices with imbedded software providing anatomic image recognition guidance for the clinician. The devices have three critical elements to assist users in locating the trachea and maneuvering the endotracheal tube.
1. Articulating tip with thumb-controlled steering
2. Continuous visualization
3. Visual guidance software
BUSINESS MODEL
Brio’s core competencies are R&D, product development, sales and marketing of medical devices. Projections are built on three revenue streams: two disposable stylets (one with and one without a camera) and a reusable video display. Brio has an agreement with a manufacturing partner to facilitate design history files, regulatory compliance, manufacturing and customer service.
FUNDING & MILESTONES
Brio has received $815,000 funding, including $690K in non-dilutive grants and $125k in convertible notes. The Company has received Small Business Investigational Research (SBIR) Grants from the NIH.
Brio Device, LLC
Commercialization OfficerChristian Renaudin
MedForce
PartnerLisa Rhoads
Easton Capital Investment Group is a venture capital firm based in New York. Easton Capital invests broadly in the life science sector, and considers investment opportunities globally. The firm is likely to make 4-6 allocations in the next 6 months. Allocations typically vary from $250,000 to $5 million, in the form of equity or convertible debt. Allocations are typically made at the venture stage of development, but may be made in seed rounds if a company already has proof of their product's efficacy.
Easton Capital
Managing DirectorAlexandra Richardson
Clayton Biotechnologies commercializes technologies that are developed and owned by the Clayton Foundation for Research and its supporting entities through research programs at leading research hospitals and institutions in the US and Switzerland.
We have several projects in various stages of development from discovery to advanced pre-clinical that are available for licensing, collaboration, and the creation of new start-up ventures.
Clayton Biotechnologies has a significant portfolio of technologies to offer for licensing and collaboration.
Some of our featured technologies:
- Urocortins and analogues for Diabetes
- Fc engineering of aglycosylated antibodies
- Granzyme B - a potent payload for antibody drug conjugates (ADC)
- Alk4-Fc, a Cripto antagonist for Cancer
- TEAD gene and peptide therapies for ocular neovascular disease
- Stem cell therapy program for Parkinson's Disease
- Vaccines and Diagnostics for Ehrlichioses
- Biomarker for personalized breast cancer therapy
- YESS - engineering of proteases
- OCT Image Guided Smart Laser Knife Diagnosis and Therapy in Small Spaces
To date, 9 products based on Clayton Foundation discoveries have been have been successfully commercialized through the creation of start-up companies and out-licensing